Key Points
- EVP John Charles Thomas sold 642 shares of Krystal Biotech on May 26 at an average price of $302.03, totaling about $193,903. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Krystal Biotech’s stock opened at $306.63, near its 52-week high of $319.48, and the company has a market value of about $9.04 billion.
- The company recently beat quarterly expectations, reporting $1.83 EPS versus the $1.45 estimate and revenue of $116.36 million. Analysts remain broadly positive, with a consensus rating of Moderate Buy and an average price target of $324.11.
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) EVP John Charles Thomas sold 642 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Krystal Biotech Price Performance
Shares of NASDAQ:KRYS opened at $306.63 on Thursday. Krystal Biotech, Inc. has a fifty-two week low of $123.03 and a fifty-two week high of $319.48. The business has a 50-day moving average of $275.34 and a two-hundred day moving average of $259.63. The stock has a market capitalization of $9.04 billion, a P/E ratio of 40.99 and a beta of 0.50.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts' consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. As a group, research analysts expect that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Krystal Biotech in a report on Friday, March 27th. They issued a "peer perform" rating for the company. HC Wainwright reissued a "buy" rating and issued a $310.00 price target on shares of Krystal Biotech in a report on Monday, May 18th. Jefferies Financial Group raised their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Citigroup raised their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a "buy" rating in a research note on Tuesday, May 5th. Finally, Wall Street Zen raised shares of Krystal Biotech from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $324.11.
Check Out Our Latest Research Report on KRYS
Hedge Funds Weigh In On Krystal Biotech
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. EFG Asset Management North America Corp. lifted its position in Krystal Biotech by 18.4% in the 3rd quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company's stock valued at $4,784,000 after acquiring an additional 4,217 shares in the last quarter. Public Sector Pension Investment Board lifted its position in Krystal Biotech by 15.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company's stock valued at $17,729,000 after acquiring an additional 13,743 shares in the last quarter. SG Americas Securities LLC lifted its position in Krystal Biotech by 469.9% in the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company's stock valued at $4,662,000 after acquiring an additional 15,591 shares in the last quarter. Atle Fund Management AB lifted its position in Krystal Biotech by 109.3% in the 3rd quarter. Atle Fund Management AB now owns 42,191 shares of the company's stock valued at $7,448,000 after acquiring an additional 22,033 shares in the last quarter. Finally, William Blair Investment Management LLC lifted its position in Krystal Biotech by 63.9% in the 3rd quarter. William Blair Investment Management LLC now owns 149,302 shares of the company's stock valued at $26,356,000 after acquiring an additional 58,203 shares in the last quarter. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
